190 completed, 53 unknown, 19 terminated, 11 recruiting. 302 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 302 | Completed 190, Unknown 53, Terminated 19, Recruiting 11, Not yet recruiting 9, Active not recruiting 8, Withdrawn 8, Enrolling by invitation 2, Suspended 2 |
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans Integrated care - Opioid Use Disorder, HIV | Not applicable | Not yet recruiting | VA Office of Research and Development | 60 | 2028-04-03 | 2026-04-24 |
| STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine Standard of Care (Patient Navigation to Off-Site Clinic), Status-Neutral Telehealth Concierge (SN-THR) - HIV, Substance Use Disorder (SUD) | Not applicable | Not yet recruiting | University of Miami | 200 | 2027-05-01 | 2026-11-12 |
| ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) - Hepatitis C | Not applicable | Not yet recruiting | Johns Hopkins University | 200 | 2026-11-01 | 2025-11-10 |
| Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 388 | 2026-11-01 | 2026-10-29 |
| Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 1660 | 2026-11-01 | 2026-10-29 |
| Strengthening, Guidance, Health, Empowerment Self-sampling for six sexually transmitted infections - HIV Infection, Syphilis | Not applicable | Not yet recruiting | University Hospital, Montpellier | 200 | 2026-09-01 | 2026-08-26 |
| Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs Partner navigation intervention booster session - HEPATITIS C (HCV), Opioid Use Disorder | Not applicable | Not yet recruiting | University of California, San Francisco | 50 | 2026-09-01 | 2026-06-08 |
| Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3) Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID) - HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV) | Not applicable | Not yet recruiting | University of Georgia | 50 | 2026-08-01 | 2025-12-18 |
| Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing PPP-CCM - HEPATITIS C (HCV) | Not applicable | Recruiting | University of Washington | 444 | 2026-06-01 | 2026-11-12 |
| Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer PIVKA-II and GAAD score calculation - Liver Cirrhosis, Hepatitis B, Chronic | Not applicable | Enrolling by invitation | Siriraj Hospital | 2100 | 2026-02-02 | 2026-04-24 |
| California MEPS Hub Mobile Enhanced Prevention Support (MEPS), Control - HIV Prevention, Sexually Transmitted Infections (STI) | Not applicable | Recruiting | University of California, Los Angeles | 318 | 2025-12-01 | 2026-04-03 |
| Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). resveratrol, quercetin, taurine, whey protein, and inulin, whey protein - Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION | Not applicable | Recruiting | University of Guadalajara | 26 | 2025-10-11 | 2026-03-23 |
| Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France Community screening for hepatitis B, C and delta in the Mongolian population living in France - HEPATITIS C (HCV), Hepatitis B Virus (HBV) | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 2000 | 2025-09-01 | 2025-06-26 |
| Hepatitis C Tracker Study GPS tracker device - Hepatitis C Virus Infection | Not applicable | Recruiting | University of Southern California | 124 | 2025-08-08 | 2025-08-29 |
| DBS TaT in Peer-assisted Telemedicine for Hepatitis C DBS TaT, Usual Care - Hepatitis C | Not applicable | Active not recruiting | Oregon Health and Science University | 141 | 2025-01-22 | 2026-06-05 |
| Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening MATCHES - Colorectal Cancer Screening, Hepatitis C Virus | Not applicable | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 350 | 2024-10-21 | 2026-09-16 |
| Lay User Evaluation of the Panbio™ HCV Self-Test Panbio™ HCV Self Test - HEPATITIS C (HCV) | Not applicable | Unknown | Abbott Rapid Dx | 1185 | 2024-10-01 | 2024-09-20 |
| Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NIATx - HIV, Hepatitis C Virus (HCV) | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 548 | 2024-10-01 | 2025-12-29 |
| Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C MagIA IBC test in capillary blood, MagIA IBC test in other blood matrices - Combined Point of Care Diagnostic of HIV, HBV and HCV | Not applicable | Terminated | MagIA Diagnostics | 96 | 2024-09-16 | 2026-09-11 |
| Hepatitis C Treatment in Idaho County Jails sofosbuvir/velpatasvir - Hepatitis C | Not applicable | Unknown | Eastern Idaho Public Health | 100 | 2024-08-01 | 2024-08-01 |
Showing 20 of 302. Sign in to see all of them.
Hepatitis C, Chronic (55) · Hepatitis B (29) · Acquired Immunodeficiency Syndrome (25) · Substance-Related Disorders (25) · HIV Infections (23) · Opioid-Related Disorders (17) · Fibrosis (13) · Liver Diseases (12) · Carcinoma, Hepatocellular (10) · Depression (10) · Hepatitis (10) · Liver Cirrhosis (7) · Alcoholism (6) · Medication Adherence (6)
Blood-Borne Infections (302) · Flaviviridae Infections (302) · Digestive System Diseases (301) · RNA Virus Infections (301) · Communicable Diseases (300) · Virus Diseases (300) · Hepatitis, Viral, Human (299) · Infections (298) · Hepatitis (292) · Liver Diseases (290) · Pathological Conditions, Signs and Symptoms (96) · Pathologic Processes (92) · Disease Attributes (73) · Chronic Disease (63) · Urogenital Diseases (61)
Ribavirin (23) · peginterferon alfa-2a (11) · Sofosbuvir (8) · Standard of Care (7) · Blood Specimen Collection (5) · daclatasvir (5) · Motivational Interviewing (4) · Telemedicine (4) · peginterferon alfa-2b (4) · sofosbuvir-velpatasvir drug combination (4) · Control Groups (3) · Early Intervention, Educational (3) · Ethanol (3) · Interferons (3) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (3)
Kirby Institute (8) · Foundation for Innovative New Diagnostics, Switzerland (7) · Johns Hopkins University (7) · VA Office of Research and Development (7) · US Department of Veterans Affairs (6) · University of La Laguna (6) · Macfarlane Burnet Institute for Medical Research and Public Health Ltd (5) · National Taiwan University Hospital (5) · University of California, Los Angeles (5) · University of California, San Francisco (5) · ANRS, Emerging Infectious Diseases (4) · Hasselt University (4) · Icahn School of Medicine at Mount Sinai (4) · Prisma Health-Upstate (4) · University of Colorado, Denver (4)
United States (148) · France (19) · Australia (13) · Canada (12) · Spain (12) · Egypt (9) · Taiwan (9) · United Kingdom (7) · Belgium (6) · Brazil (5) · China (5) · Israel (5) · Thailand (5) · Georgia (4) · Germany (4)
Adeline Nyamathi, PhD (2) · Alain Litwin, MD (2) · Alain Litwin, MD, MPH (2) · Ali Ismail, lecturer (2) · Amy Silberbogen, PhD (2) · Frederick L Altice, MD (2) · Geert Robaeys, prof. dr. (2) · Jason Haukoos, MD, MSc (2) · Jennifer J Kiser, PharmD (2) · Jennifer Kiser, PharmD (2) · Jens Rosenau, MD (2) · Kristen Marks (2) · Manuel Hernandez-Guerra, MD (2) · Mark Sulkowski, MD (2) · Rob Bielen, dr. (2)
PMID 10761562, PMID 10921388, PMID 10965678, PMID 11059069, PMID 11059125, PMID 11413125, PMID 12450640, PMID 12618532, PMID 12761382, PMID 12823087, PMID 15560058, PMID 15637534, PMID 15784668, PMID 16122679, PMID 17410291, PMID 17451562, PMID 17552026, PMID 17695343, PMID 17980513, PMID 18233994, PMID 18495540, PMID 18807097, PMID 19638084, PMID 19897823, PMID 20091629, PMID 20332290, PMID 20479894, PMID 20491973, PMID 20529203, PMID 20608766, PMID 20638216, PMID 21218306, PMID 21241735, PMID 21301463, PMID 21767252, PMID 21782772, PMID 21911884, PMID 22078241, PMID 22419935, PMID 23059806, PMID 23155727, PMID 23241251, PMID 23300053, PMID 23333451, PMID 23445604, PMID 23607593, PMID 23607594, PMID 23750991, PMID 24428467, PMID 24782620
P30AI042853 (2), 1IK2CX002822-01A1 (1), 1UL1TR001430 (1), 2008 (1), 4UH3DA044798-03 (1), 4UH3DA044829-03 (1), DP2DA053720 (1), I50HX002903 (1), K01DA059329 (1), K23AA023753 (1), K23DA022454 (1), K23DA039060 (1), K23DK089004 (1), K24DA061103 (1), K24DK066144 (1)